-
Something wrong with this record ?
Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups
Z. Pavelek, M. Novotny, O. Soucek, J. Krejsek, L. Sobisek, I. Sejkorova, J. Masopust, K. Kuca, M. Valis, B. Klimova, P. Stourac
Language English Country Netherlands
Document type Journal Article
- MeSH
- Biomarkers MeSH
- Glatiramer Acetate therapeutic use MeSH
- Interferon beta-1a MeSH
- Humans MeSH
- Multiple Sclerosis, Relapsing-Remitting * drug therapy MeSH
- Multiple Sclerosis * drug therapy MeSH
- T-Lymphocytes MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system (CNS). T cells and B lymphocytes are involved in the development of this disease. METHODS: The following biomarkers were determined in peripheral blood in 28 patients treated with glatiramer acetate (GA) and 21 patients treated with interferon beta 1-a (IFN): IL-10, BAFF, Mx1, IgG, IgG1, IgG2, IgG3 and IgG4 (at baseline and after 6 months of treatment). All participants had confirmed MS diagnosis. OBJECTIVES: The primary objective is to assess a percentual change of biomarkers after 6 months since the first-line treatment initiation with GA or IFN. The secondary objective is to explore correlations between the baseline biomarkers' values (levels). RESULTS: A positive trend was observed in the increase in IL-10 concentration by 30.33 % (IFN) and by 15.65 % (GA). In the IFN group, we observed a statistically significant increase in the BAFF protein concentration by 29.9% (P < 0.001). We found that Mx1 protein levels did not change with the administration of GA, which can be explained by the different mechanisms of action of GA. The serum levels of IgG immunoglobulins and both IgG1 and IgG4 subclasses in both groups of patients were increased. Thus, our data were in accordance with the generally accepted assumption that both IFN and GA are capable of modulating the B cell system. CONCLUSIONS: Our results suggest that treatment with IFN and GA has a more pronounced influence on the B cell system of MS.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025257
- 003
- CZ-PrNML
- 005
- 20211026134001.0
- 007
- ta
- 008
- 211013s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2021.103082 $2 doi
- 035 __
- $a (PubMed)34166982
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Pavelek, Zbysek $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. Electronic address: zbysekpavelek@email.cz
- 245 10
- $a Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups / $c Z. Pavelek, M. Novotny, O. Soucek, J. Krejsek, L. Sobisek, I. Sejkorova, J. Masopust, K. Kuca, M. Valis, B. Klimova, P. Stourac
- 520 9_
- $a BACKGROUND: Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system (CNS). T cells and B lymphocytes are involved in the development of this disease. METHODS: The following biomarkers were determined in peripheral blood in 28 patients treated with glatiramer acetate (GA) and 21 patients treated with interferon beta 1-a (IFN): IL-10, BAFF, Mx1, IgG, IgG1, IgG2, IgG3 and IgG4 (at baseline and after 6 months of treatment). All participants had confirmed MS diagnosis. OBJECTIVES: The primary objective is to assess a percentual change of biomarkers after 6 months since the first-line treatment initiation with GA or IFN. The secondary objective is to explore correlations between the baseline biomarkers' values (levels). RESULTS: A positive trend was observed in the increase in IL-10 concentration by 30.33 % (IFN) and by 15.65 % (GA). In the IFN group, we observed a statistically significant increase in the BAFF protein concentration by 29.9% (P < 0.001). We found that Mx1 protein levels did not change with the administration of GA, which can be explained by the different mechanisms of action of GA. The serum levels of IgG immunoglobulins and both IgG1 and IgG4 subclasses in both groups of patients were increased. Thus, our data were in accordance with the generally accepted assumption that both IFN and GA are capable of modulating the B cell system. CONCLUSIONS: Our results suggest that treatment with IFN and GA has a more pronounced influence on the B cell system of MS.
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a glatiramer acetát $x terapeutické užití $7 D000068717
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interferon beta 1a $7 D000068556
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 _2
- $a T-lymfocyty $7 D013601
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Novotny, Michal $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Soucek, Ondrej $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Krejsek, Jan $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Sobisek, Lukas $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Sejkorova, Ilona $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Masopust, Jiri $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kuca, Kamil $u Department of Chemistry, University of Hradec Kralove, Faculty of Science, Hradec Kralove, Czech Republic
- 700 1_
- $a Valis, Martin $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Klimova, Blanka $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Stourac, Pavel $u Department of Neurology, Masaryk University, Faculty of Medicine and University Brno, Brno, Czech Republic
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 53, č. - (2021), s. 103082
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34166982 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134007 $b ABA008
- 999 __
- $a ok $b bmc $g 1714353 $s 1145764
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 53 $c - $d 103082 $e 20210615 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20211013
